Context Therapeutics Inc. (CNTX): Depreciation & Amortization
$16.3K
Year ended 2025-12-31
$19.5K
Trailing 12 months to 2026-06-30
+20.6%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.3K | +49.4% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $10.9K | -9.7% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $12.0K | +30.0% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $9.3K | n/a | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $0 | n/a | 2023-03-22, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $16.3K | +49.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $0 | -100.0% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $105.0K | +23.5% |
| Rallybio Corp (RLYB) | 2025-12-31 | $92.0K | -29.8% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $447.0K | -2.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $2.77M | -12.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.83M | -21.9% |
Compare CNTX, SPRO, CRVS, RLYB side by side · Screen every company in Pharmaceutical Preparations ↗